Omnia Biologics and Sumagen Announce Successful Manufacture of HIV/AIDS Vaccine Phase I Material

ROCKVILLE, Md.--()--Omnia Biologics, Inc. (Rockville, MD) and Sumagen Co., Ltd. (London, ON) today jointly announced the successful completion of cGMP manufacture of Sumagen’s HIV/AIDS vaccine for a Phase I clinical trial. Safe, effective vaccines for HIV prophylaxis and therapy remain a vital and elusive goal in the fight against infectious disease. The need for new clinical candidates for HIV/AIDS is pressing since recent failures of other late stage products.

“The team at Omnia is very pleased to have assisted Sumagen in this important effort addressing the new priorities of the path forward in the wake of the STEP study,” commented Dr. Dale VanderPutten, CEO of Omnia Biologics. “Sumagen, like many companies in the experimental biologics space, has had great difficulty in finding suitable contract manufacturing expertise to move their products into clinical trials. After the failure of other CMOs, we are happy that Omnia’s customer focused and product specialized services were able to satisfy 250% of their required yield on schedule.”

“We are very pleased to be taking this important step forward in advancing our HIV/AIDS vaccine into clinical trials. We thank Omnia for their assistance in this endeavor,” stated Dr. Sangkyun Lee, Vice President, Sumagen Co., Ltd.

About Omnia Biologics: (www.omniabiologics.com)

Omnia offers contract services for biotechnology and pharmaceutical companies in process development, GMP manufacture, and fill-finish for preclinical and Phase I clinical programs of novel therapeutics having significant manufacturing challenges. These products include vaccines, autologous therapeutics, new gene therapeutic platforms, and stem cell technologies. The company seeks and has established relationships with both biopharmaceutical companies and academic investigators throughout the world.

About Sumagen: (www.sumagen.com)

Sumagen Co., Ltd. is a Korean pharmaceutical venture company focusing on developing HIV/AIDS vaccine supported by Curocom Co. Ltd. Sumagen is also supporting a HCV vaccine program which is ongoing research in University of Western Ontario (UWO) in Canada.

Contacts

Omnia Biologics, Inc.
Sami Cardak, 301-984-5928
Fax: 301-984-2515
scardak@omniabio.com
or
Sumagen Canada Inc.
Eunsil Choi, 519-858-5125
Fax: 519-858-5046
eschoi@curocom.com

Contacts

Omnia Biologics, Inc.
Sami Cardak, 301-984-5928
Fax: 301-984-2515
scardak@omniabio.com
or
Sumagen Canada Inc.
Eunsil Choi, 519-858-5125
Fax: 519-858-5046
eschoi@curocom.com